Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens

• DOI: 10.1111/all.15327
• Publication Date: 2022-04-27T04:58:33Z
• Authors: Ekaterina Potapova; Véronique Bordas‐...; Thomas Schlederer; Susanne Vrtala; Huey‐Jy Huang; Giorgio W. Canonica; Rudolf Valenta; Paolo M. Matricardi; Laurent Mascarell
• Keywords: Allergen Immunotherapy; Pyroglyphidae; Sublingual administration

Molecular antibody reactivity profiles have not yet been studied in depth patients treated by sublingual house dust mite (HDM) tablet immunotherapy. Humoral immune responses to a large panel of HDM allergens were using allergen microarray technology subset clinically defined high and low responder from double-blind placebo-controlled allergen-specific immunotherapy (AIT) trial 300 IR tablets.Serum levels IgE, IgG IgG4 13 Dermatophagoides pteronyssinus molecules measured at baseline after 1-year AIT, microarrays 100 subjects exhibiting or clinical benefit.Der p 1, Der 2 23 the most frequently recognized study population. Patients with HDM-related asthma had significantly higher IgE 1 23. No significant difference distribution sensitization pattern was observed between responders. An increase serum occurred upon particular (p < 0.0001).We confirm for our population that 1- 23-specific are associated asthma. predicitive AIT outcomes, tablets as efficacious pauci- multi-sensitized subjects. Our is first demonstrate induction specific AIT.